Leukocyte- and Platelet-Rich Fibrin versus Commercially Available Fibrin Sealants in Elective Cranial Surgery: A Cost-Minimization Analysis

Abstract

BackgroundPrevious findings from a clinical trial demonstrated non-inferiority of Leukocyte- and platelet-rich fibrin (L-PRF) compared to commercially available fibrin sealants in preventing postoperative cerebrospinal fluid (CSF) leakage, necessitating intervention. This cost-effectiveness evaluation aims to assess the value-for-money of both techniques for dural closure in supratentorial and infratentorial surgeries. MethodsCost-effectiveness was estimated from a healthcare payer’s perspective alongside a randomized clinical trial comprising 328 patients. The analysis focused on clinical and health-related quality of life (HRQOL) outcomes, as well as direct medical costs including inpatient costs, imaging and laboratory costs, and outpatient follow up costs up to twelve weeks after surgery. ResultsClinical and HRQOL data showed no significant differences between L-PRF (EQ5D 0.75 ± 0.25, SF-36 63.93% ± 20.42) and control (EQ5D 0.72 ± 0.22, SF-36 60.93% ± 20.78) groups. Pharmaceutical expenses during initial hospitalization were significantly lower in the L-PRF group (€190.4, IQR 149.9) than in the control group (€394.4, IQR 364.3), while other cost categories did not show any significant differences, resulting in an average cost advantage of €204 per patient favoring L-PRF. ConclusionThis study demonstrates L-PRF as a cost-effective alternative for commercially available fibrin sealants in dural closure. Implementing L-PRF can lead to substantial cost savings, particularly considering the frequency of these procedures.